Correlation of neutrophil-lymphocyte ratio, plateletlymphocyte ratio and mean platelet volume with disease activity in patients with ankylosing spondylitis

Therefore, NLR and PLR can be used as potential parameters for the assessment of disease activity and extra-spinal disease and treatment response monitoring in patients with AS

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objectives: The indices that are currently used to determine the disease activity in patients with ankylosing spondylitis (AS) are either patient- or physician-oriented.

📊

Key Findings & Data:Methods: This cross-sectional observational study was performed on 60 patients with definite AS in a tertiary care hospital in New Delhi, India.

💡

Conclusion & Impact:Therefore, NLR and PLR can be used as potential parameters for the assessment of disease activity and extra-spinal disease and treatment response monitoring in patients with AS

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Objectives: The indices that are currently used to determine the disease activity in patients with ankylosing spondylitis (AS) are either patient- or physician-oriented. The neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR) and mean platelet volume (MPV) are new markers of systemic inflammation and correlate with disease severity in many rheumatological disorders. However, their relationship with disease activity in patients with AS has not been thoroughly studied in the Indian subcontinent. Methods: This cross-sectional observational study was performed on 60 patients with definite AS in a tertiary care hospital in New Delhi, India. Healthy, age- and sex-matched individuals identified from the same demographic population were subjected to clinical assessment and investigations as per protocol. Results: The mean values of NLR, PLR and MPV were 3.13±1.1, 168.36±69.43 and 10.07±1.28, respectively, in cases with high disease activity as compared to 2.58±1.05, 127.02±55.65 and 10.07±1.64 in cases with low disease activity. A statistically significant correlation was found between NLR and PLR and disease activity as calculated by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Metrology Index (BASMI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Ankylosing Spondylitis Disease Activity Score-C-reactive protein/erythrocyte sedimentation rate (ASDAS-CRP/ESR). However, multivariate linear regression revealed a significant correlation only between NLR and BASDAI, BASFI and ASDAS-CRP. PLR was found to be significantly lower in cases on biological therapy. No correlation of PLR and MPV with disease activity was found on multivariate regression analysis. Conclusion: NLR and PLR correlate significantly with disease activity indices in patients with AS. Patients with the extraspinal disease had higher NLR, PLR and MPV with only NLR being statistically significant. NLR was significantly lower in patients on biologics than those on Disease modifying antirheumatic drugs (DMARDs). Therefore, NLR and PLR can be used as potential parameters for the assessment of disease activity and extra-spinal disease and treatment response monitoring in patients with AS

🔖

Cite This Article

GUPTA, P. K., SHEORAN, A., KHATAK, M., BALANKHE, K., KONER, S., NAYAK, R., JİNDAL, K., SİNGH, S. K. (2022). Correlation of neutrophil-lymphocyte ratio, plateletlymphocyte ratio and mean platelet volume with disease activity in patients with ankylosing spondylitis. International Journal of Medical Biochemistry, Cilt: 5 - Sayı: 1, 15–20. https://ajindex.com/articles/541402

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al; Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(1):18–24
Spoorenberg A, van Tubergen A, Landewé R, Dougados M, van der Linden S, Mielants H, et al. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 2005;44(6):789–95
Danve A, O'Dell J. The ongoing quest for biomarkers in Ankylosing Spondylitis. Int J Rheum Dis 2015;18(8):826–34
Kucuk A, Uslu AU, Ugan Y, Bagcaci S, Karahan AY, Akarmut A, et al. Neutrophil-to-lymphocyte ratio is involved in the severity of ankylosing spondylitis. Bratisl Lek Listy 2015;116(12):722–5
Erkol Inal E, Sunar İ, Saratas S, Eroğlu P, İnal S, Yener M. May Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios Indicate Disease Activity in Ankylosing Spondylitis? Arch Rheumatol 2015;30(2):130–7
Sezgin M, Tecer D, Kanık A, Kekik FS, Yeşildal E, Akaslan E, et al. Serum RDW and MPV in Ankylosing Spondylitis: Can they show the disease activity? Clin Hemorheol Microcirc 2017;65(1):1–10
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21(12):2286–91
Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21(12):2281–5
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21(9):1694–8
Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al; Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70(1):47–53
Gökmen F, Akbal A, Reşorlu H, Gökmen E, Güven M, Aras AB, et al. Neutrophil-lymphocyte ratio connected to treatment options and inflammation markers of ankylosing spondylitis. J Clin Lab Anal 2015;29(4):294–8
Xu S, Ma Y, Wu M, Zhang X, Yang J, Deng J, et al. Neutrophil lymphocyte ratio in patients with ankylosing sp